Evergreen - Stock Earnings

AbbVie vs. JNJ: Which Biopharma Stock Wins in 2026?

Biopharma stocks may benefit from sector rotation. AbbVie and Johnson & Johnson deserve a close look, but they are not the same trade.

FIFA World Cup betting boom may lift DraftKings and ETFs like DRAY and BETZ, creating new opportunities across the sports gaming sector.

Three REITs offering dependable income, dividend growth, and stability as investors seek safe-haven opportunities amid market uncertainty.

Robinhood isn’t a brokerage with a crypto problem. It’s a vertically integrated financial platform under construction.

Citi warns gold could drop up to 20% by September, but long-term forecasts from JPMorgan and Goldman remain strongly bullish.

Rising oil prices and growing geopolitical tensions could create opportunities for investors through diversified energy ETFs.

OpenAI IPO excitement is growing. These three ETFs and funds offer investors exposure to AI and IPO trends before potential public listings.

The new space race isn’t about tourism or Mars. It’s about building the systems that let nations launch faster, see farther, and act sooner.

The AI selloff looks like a reset in expectations, not fundamentals, with tech stocks still executing well.

AI boom could push the S&P 500 toward 8,000 by 2026 as analysts point to strong fundamentals and rising demand.